JEFFERY WILLIAM KELLY
Pilots at El Paseo Grande, La Jolla, CA
License number
California A2164738
Issued Date
May 2016
Expiration Date
May 2018
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
8110 El Paseo Grande UNIT 407, La Jolla, CA 92037
Professional information
Reliable Stabilization Of N-Linked Polypeptide Native States With Enhanced Aromatic Sequons Located In Polypeptide Tight Turns
US Patent:
2013003, Feb 7, 2013
Filed:
Aug 2, 2012
Appl. No.:
13/565502
Inventors:
Jeffery W. Kelly - La Jolla CA, US
Joshua L. Price - Vineyard UT, US
Elizabeth K. Culyba - Arlington MA, US
Evan T. Powers - San Diego CA, US
Joshua L. Price - Vineyard UT, US
Elizabeth K. Culyba - Arlington MA, US
Evan T. Powers - San Diego CA, US
International Classification:
C07K 14/00, C07K 16/00, C07K 16/28, C07K 14/575, C07K 14/62, C07K 14/755, C07K 14/745, C07K 14/505, C07K 14/55, C07K 14/535, C07K 14/59, C07K 14/57, A61K 38/14, A61K 39/395, A61K 38/22, A61K 38/16, C12N 9/68, C12N 9/70, C12N 9/74, C12N 9/72, C12N 9/64, C12P 21/02, C07K 4/00
US Classification:
4241331, 530300, 530402, 5303873, 530399, 530303, 530383, 530381, 530380, 530351, 530397, 530398, 530322, 530395, 514 209, 514 97, 435217, 435216, 435214, 435215, 435226, 435 691
Abstract:
A chimeric therapeutic polypeptide of a pre-existing therapeutic polypeptide is disclosed, as are a method of enhancing folded stabilization and a pharmaceutical composition of the glycosylated chimer. The pre-existing and chimeric polypeptides have substantially the same length, substantially the same amino acid residue sequence, and exhibit at least one tight turn containing a sequence of four to about seven amino acid residues in which at least two amino acid side chains extend on the same side of the tight turn and are within less than about 7 Å of each other. The chimeric therapeutic polypeptide has the sequon Aro-(Xxx)n-(Zzz)p-Asn-Yyy-Thr/Ser (SEQ ID NO:001) within that tight turn sequence such that the side chains of the Aro, Asn and Thr/Ser amino acid residues project on the same side of the turn and are within less than about 7 Å of each other. That sequon is absent from the pre-existing therapeutic polypeptide.
Transthyretin Stabilization
US Patent:
2008031, Dec 25, 2008
Filed:
May 20, 2005
Appl. No.:
11/596832
Inventors:
Jeffery W. Kelly - La Jolla CA, US
H. Michael Petrassi - Cardiff CA, US
H. Michael Petrassi - Cardiff CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C07K 14/47, C07D 307/91
US Classification:
530410, 549461
Abstract:
Dibenzofuran-4,6-dicarboxylic acid core structures having an aromatic substituent appended onto the at the C1 position using three different types of linkages are disclosed herein and shown to afford exceptional amyloidogenesis inhibitors that display increased affinity and greatly increased binding selectivity to TTR over all the other plasma proteins, relative to lead compound 1. It is further disclosed herein that these compounds function by imposing kinetic stabilization on the TTR tetramer.
Methods For Treating Transthyretin Amyloid Diseases
US Patent:
2012006, Mar 15, 2012
Filed:
Nov 22, 2011
Appl. No.:
13/303060
Inventors:
Jeffery W. KELLY - La Jolla CA, US
Evan T. POWERS - La Jolla CA, US
Hossein RAZAVI - Danbury CT, US
Evan T. POWERS - La Jolla CA, US
Hossein RAZAVI - Danbury CT, US
Assignee:
THE SCRIPPS RESEARCH INSTITUTE - La Jolla CA
International Classification:
A61K 31/423, A61P 9/00, A61P 25/00
US Classification:
514375
Abstract:
Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed.
Genistein Inhibition Of Transthyretin Amyloidosis
US Patent:
2007003, Feb 15, 2007
Filed:
Aug 11, 2006
Appl. No.:
11/504134
Inventors:
Jeffery Kelly - La Jolla CA, US
Nora Green - Mechanicsville VA, US
Nora Green - Mechanicsville VA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 31/353
US Classification:
514456000
Abstract:
Genistein is an excellent transthyretin amyloidogenesis inhibitor and exhibits excellent binding selectivity in plasma. Treatment of patients having transthyretin amyloidosis with therapeutic agents containing genistein is disclosed to ameliorate the disease condition.
Compounds, Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
US Patent:
2005027, Dec 8, 2005
Filed:
May 20, 2005
Appl. No.:
11/134848
Inventors:
Jeffery Kelly - La Jolla CA, US
International Classification:
A61K031/69, A61K031/195, A61K031/19, A61K031/192, A61K031/41
US Classification:
514064000, 514381000, 514568000, 514575000, 548252000, 562007000, 562488000, 562621000, 514567000, 562440000
Abstract:
Compounds, compositions and methods are provided for stabilizing transthyretin and for treating, preventing, or ameliorating one or more symptoms of transthyretin mediated diseases. In one embodiment, the compounds are biphenyls and related compounds.
Transthyretin Stabilization
US Patent:
2005026, Nov 24, 2005
Filed:
May 20, 2005
Appl. No.:
11/134527
Inventors:
Jeffery Kelly - La Jolla CA, US
H. Petrassi - Cardiff CA, US
H. Petrassi - Cardiff CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C07D307/91, A61K031/343
US Classification:
514468000, 549461000
Abstract:
Dibenzofuran-4,6-dicarboxylic acid core structures having an aromatic substituent appended onto the at the C1 position using three different types of linkages are disclosed herein and shown to afford exceptional amyloidogenesis inhibitors that display increased affinity and greatly increased binding selectivity to TTR over all the other plasma proteins, relative to lead compound 1. It is further disclosed herein that these compounds function by imposing kinetic stabilization on the TTR tetramer.
Pharmaceutically Acceptable Salt Of 6-Carboxy-2-(3,5 Dichlorophenyl)-Benzoxazole, And A Pharmaceutical Composition Comprising The Salt Thereof
US Patent:
8168663, May 1, 2012
Filed:
Jun 9, 2009
Appl. No.:
12/481527
Inventors:
Jeffery W. Kelly - La Jolla CA, US
Evan T. Powers - La Jolla CA, US
Hossein Razavi - Danbury CT, US
Evan T. Powers - La Jolla CA, US
Hossein Razavi - Danbury CT, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
A61K 31/423
US Classification:
514375, 548224, 548236
Abstract:
Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods are disclosed.
Compositions And Methods For Stabilizing Transthyretin And Inhibiting Transthyretin Misfolding
US Patent:
7214695, May 8, 2007
Filed:
Dec 19, 2003
Appl. No.:
10/741649
Inventors:
Jeffery W. Kelly - La Jolla CA, US
Evan T. Powers - La Jolla CA, US
Hossein Razavi - Danbury CT, US
Evan T. Powers - La Jolla CA, US
Hossein Razavi - Danbury CT, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C07D 263/57, A61K 31/4245
US Classification:
514375, 548224
Abstract:
Kinetic stabilization of the native state of transthyretin is an effective mechanism for preventing protein misfolding. Because transthyretin misfolding plays an important role in transthyretin amyloid diseases, inhibiting such misfolding can be used as an effective treatment or prophylaxis for such diseases. Treatment methods, screening methods, as well as specific transthyretin stabilizing compounds are disclosed.
Inhibitors Of Transthyretin Amyloid Fibril Formation
US Patent:
2009005, Feb 26, 2009
Filed:
Feb 8, 2006
Appl. No.:
11/884073
Inventors:
Jeffery W. Kelly - La Jolla CA, US
Steven M. Johnson - San Diego CA, US
H. Michael Petrassi - Cardiff CA, US
Steven M. Johnson - San Diego CA, US
H. Michael Petrassi - Cardiff CA, US
Assignee:
THE SCRIPPS RESEARCH INSTITUTE - LA JOLLA CA
International Classification:
C07K 14/47, C07C 251/86, C07C 251/32
US Classification:
530380, 564251, 564265
Abstract:
Bisaryloxime ethers and bisarylhydroazones are shown to be effective for inhibiting formation of amyloid fibrils of transthyretin.
Inhibitors Of Transthyretin Amyloid Fibril Formation
US Patent:
7312361, Dec 25, 2007
Filed:
Feb 8, 2006
Appl. No.:
11/350664
Inventors:
Jeffery W. Kelly - La Jolla CA, US
Steven M. Johnson - San Diego CA, US
H. Michael Petrassi - Cardiff CA, US
Steven M. Johnson - San Diego CA, US
H. Michael Petrassi - Cardiff CA, US
Assignee:
The Scripps Research Institute - La Jolla CA
International Classification:
C07C 243/22, C07C 251/32, C07C 229/00
US Classification:
564251, 564265, 562433, 562439
Abstract:
Bisaryloxime ethers and bisarylhydroazones are shown to be effective for inhibiting formation of amyloid fibrils of transthyretin.